Leiden University Scholarly Publications

Persistent URL of this record https://hdl.handle.net/1887/108004

In Collections

This item can be found in the following collections:

Drooger, J.C.; Tinteren, H. van; Groot, S.M. de; Tije, A.J. ten; Graaf, H. de; Portielje, J.E.A.; ... ; Sleijfer, S. (2015)

Results from a randomized phase II study of the Dutch Breast Cancer Research Group (BOOG 2008-03): Concomitant trastuzumab, bevacizumab and paclitaxel (HAT) versus trastuzumab and bevacizumab, followed by trastuzumab, bevacizumab and paclitaxel (HA- HAT) a

Article / Letter to editor
All authors
Drooger, J.C.; Tinteren, H. van; Groot, S.M. de; Tije, A.J. ten; Graaf, H. de; Portielje, J.E.A.; Jager, A.; Honkoop, A.H.; Linn, S.C.; Kroep, J.R.; Erdkamp, F.L.G.; Hamberg, P.; Heijns, J.B.; Leeuwen-Stok, A.E. van; Sleijfer, S.
Date
2015-05-01
Journal
Cancer Research
Volume
75
Issue
9